Omigapil

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameOmigapil
Drug Alias Name奥米加匹omigapiloOmigapilumCGP-3466BCGP-3466 maleate +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlyceraldehyde-3-phosphate dehydrogenase liver inhibitors
TargetsGlyceraldehyde-3-phosphate dehydrogenase liver
Therapy Area/IndicationsMuscular AtrophyAmyotrophic Lateral SclerosisParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSanthera Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanthera PharmaceuticalsNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsMuscular AtrophyAmyotrophic Lateral SclerosisParkinson Disease

Other Information

ATC CodeN/A
Related LinksN/A